Sonographic Features of Fibroids Before and During Non-surgical Therapy and/or Expectant Management

Trial Title: Sonographic Features of Fibroids Before and During Non-surgical Therapy and/or Expectant Management

NCT ID: NCT05741671

Condition: Fibroid Uterus

Conditions: Official terms:
Leiomyoma
Myofibroma

Conditions: Keywords:
fibroid
power doppler
vascularization

Study type: Observational

Overall status: Recruiting

Study design:

Time perspective: Prospective

Intervention:

Intervention type: Other
Intervention name: Questionnaire
Description: Extra in the context of the study are questionnaires which last a maximum of 5-15 minutes. The treatment considering the fibroid(s) is independent of this research. the Also the outcome measures include vaginal ultrasound, questionaires and a hemoglobin test. These measurements are applied in daily practice, as standard care.
Arm group label: Selective progesterone receptor modulators treatment or GnRH-analogues treatment
Arm group label: ablation therapy
Arm group label: after initiation exogenous hormonal exposure
Arm group label: during long-term use of exogenous hormone exposure
Arm group label: embolization therapy
Arm group label: natural course

Summary: Rationale: 20-30% of women of reproductive age have leiomyomas, causing symptoms like dysmenorrhea and pelvic pain which both effect quality of life.[1-4] The natural behaviour of uterine fibroids is to grow between 7 to 84% in 3 to 12 months.[5-7] Non-surgical options to treat uterine fibroids are non-hormonal or hormonal medical therapies and minimally invasive interventional radiologic techniques. Exogenous hormone exposure including COC, POP or Mirena give in conflicting literature minimal growth to 60% volume shrinkage. [8, 9]] Selective progesterone receptor modulators (SPRM) eg. Esmya and GnRH-analogues intent to reduce fibroids volume after several months; GnRH-agonists provide a 31-63% shrinkage and less frequently applied GnRH-antagonists 14.3 - 42.7%.[10-16] Esmya gives a volume reduction varying between 10 to 48%.[17] Radiological technique like embolization decreases dominant fibroid volume with 40-70%.[1, 18-22] UAE fails in case of devascularized or minimal vascularized fibroids.[23] Ablation techniques show shrinkage up to a maximum of 90% depending e.g. which treatment.[24-41] Clear prognostic models to predict the effect on fibroid related symptoms and volume reduction are lacking. We postulate higher vascularity to be related to 1) larger fibroid growth during the natural course or during exogenous hormonal exposure; 2) more effective shrinkage during progestogens, GnRH-analogues, SPRM and UAE; but 3) less effective after ablation therapy. Objectives: To study the value of sonographic features including vascularity in the prediction of fibroids' volume change at follow-up during their (1) natural course or (2) long-term use of exogenous hormone exposure; after initiation of (3) SPRM or GnRH-analogues treatment or (4) exogenous hormonal exposure; or after (5) embolization or (6) ablation therapy. Study design: Observational cohort study during 5 years in the outpatient clinic. Patientselection: Women ≥18 years with 1 to 3 fibroids with a maximal diameter ≥ 3cm and ≤ 10cm diagnosed on ultrasound examination, planned for expectant or non-surgical management. Study objectives: The primary outcome is volume reduction after 3 to 12 month depending on the study group. The secondary outcome include UFS-QOL, EQ-5D score, PBAC, hemoglobin level, treatment failure rate and (re)intervention rate. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: No risks are associated with the participation of this observational study since the outcome measures include vaginal ultrasound, questionaires and a hemoglobin test. These measurements are also applied in daily practice, the burden for the patient is time. Extra in the context of the study are questionnaires which last a maximum of 5-15 minutes. The treatment considering the fibroid(s) is independent of this research.

Criteria for eligibility:

Study pop:
Women pre- to perimenopausal with uterus myomatosis. Uterus myomatosis occurs in 20-30% of women of reproductive age.

Sampling method: Non-Probability Sample
Criteria:
Inclusion Criteria: - 1 to 3 fibroids - maximal diameter ≥1.5 cm and ≤ 10 cm - diagnosed on ultrasound examination with informed consent - planned for expectant management or non-surgical management in the follwing groups: 1. Women with uterine fibroids without treatment (during natural course); 2. Women with uterine fibroids using exogenous hormone exposure for at least 3 months: e.g. COC, POP, DP or LNG-IUD; 3. Women with uterine fibroids before and after/during treatment with SPRMs or GnRH-analogues; 4. Women with uterine fibroids before and after/during treatment with exogenous hormones; 5. Women with uterine fibroids before and after embolization; 6. Women with uterine fibroids before and after ablation therapy*. - In case of embolization or ablation: inclusion in case of multiple fibroids is allowed, if ≥ 1 fibroid is accessible for transvaginal ultrasound. Exclusion Criteria: - Any fibroid treatment in the last 3 months in case of (3) SPRMs or GnRH-analogues (except for exogenous hormone exposure) or (1) no treatment Age < 18 years - Fibroids not accessible for transvaginal ultrasonography - Suspicion for malignancy - Postmenopausal - Severe adenomyosis - Pregnancy - Contra-indication for the planned treatment - Use of aromatase inhibitors or tamoxifen Infertility treatment with use of clomifene and/or follicle-stimulating hormone Breastfeeding

Gender: Female

Gender based: Yes

Gender description: Fibroids are uterine-related

Minimum age: 18 Years

Maximum age: N/A

Healthy volunteers: No

Locations:

Facility:
Name: Amsterdam UMC

Address:
City: Amsterdam
Zip: 1105AZ
Country: Netherlands

Status: Recruiting

Contact:
Last name: Judith Huirne, Prof.
Email: j.huirne@amsterdamuc.nl

Start date: September 24, 2018

Completion date: September 2023

Lead sponsor:
Agency: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Agency class: Other

Source: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT05741671